ARCT ARCTURUS THERAPEUTICS HOLDINGS INC Product Launches 8-K Filing 2024 - COVID-19 Vaccine Success Arcturus Therapeutics' COVID-19 vaccine candidate met the primary endpoint in a Phase III clinical study in Japan, according to a press release by Meiji Seika Pharma.Get access to all SEC 8-K filings of the ARCTURUS THERAPEUTICS HOLDINGS INC